AMG National Trust Bank Takes Position in Edwards Lifesciences Corporation $EW

Key Points

• AMG National Trust Bank acquired a new stake of 75,472 shares in Edwards Lifesciences (EW) during Q4, valued at about $6.43 million, and institutional investors now own roughly 79.46% of the stock.
• Edwards beat Q results with $0.78 EPS vs. $0.73 estimate and $1.65B revenue vs. $1.60B estimate, issued FY2026 guidance of 2.950–3.050 EPS, and carries a MarketBeat consensus of "Moderate Buy" with an average price target of $95.65.
• Corporate insiders have sold 86,058 shares (~$7.12M) in the last three months, while the stock trades near $83.51 with a market cap of $48.15 billion and a P/E of 45.63.

AMG National Trust Bank acquired a new stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 75,472 shares of the medical research company's stock, valued at approximately $6,434,000.

Several other hedge funds also recently added to or reduced their stakes in EW. JPL Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the 3rd quarter worth $25,000. True Wealth Design LLC raised its holdings in Edwards Lifesciences by 251.5% in the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company's stock valued at $28,000 after buying an additional 259 shares during the period. Hantz Financial Services Inc. raised its holdings in Edwards Lifesciences by 76.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company's stock valued at $29,000 after buying an additional 164 shares during the period. Dorato Capital Management acquired a new position in Edwards Lifesciences in the fourth quarter valued at about $29,000. Finally, Rakuten Securities Inc. lifted its position in Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company's stock valued at $29,000 after buying an additional 302 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Down 0.8%

Shares of EW stock opened at $83.51 on Tuesday. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $87.89. The company has a 50 day moving average price of $81.86 and a 200 day moving average price of $82.35. The stock has a market capitalization of $48.15 billion, a P/E ratio of 45.63, a price-to-earnings-growth ratio of 2.18 and a beta of 0.95. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 14.45%. The company had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same period in the prior year, the business earned $0.64 EPS. The firm's quarterly revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts predict that Edwards Lifesciences Corporation will post 2.98 EPS for the current fiscal year.

Insider Activity

In related news, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction on Monday, April 6th. The stock was sold at an average price of $80.98, for a total value of $82,518.62. Following the completion of the transaction, the vice president directly owned 33,934 shares in the company, valued at approximately $2,747,975.32. This trade represents a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the business's stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the transaction, the chief financial officer directly owned 39,699 shares of the company's stock, valued at $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 86,058 shares of company stock worth $7,118,636. Corporate insiders own 0.31% of the company's stock.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Mizuho set a $95.00 price objective on shares of Edwards Lifesciences and gave the stock an "outperform" rating in a report on Monday, April 13th. Stifel Nicolaus set a $110.00 price objective on shares of Edwards Lifesciences and gave the stock a "buy" rating in a research report on Tuesday, January 20th. The Goldman Sachs Group reiterated a "buy" rating and issued a $95.00 target price (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Finally, Canaccord Genuity Group set a $85.00 price target on Edwards Lifesciences and gave the stock a "hold" rating in a research note on Friday. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $95.65.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.